Protein splice renders statins inefffective for some

One more tiny step in the long march toward personalized drug treatment: Researchers found a protein quirk that makes statins less than effective in some people. The protein, called UMGCR, plays a role in producing LDL, or "bad" cholesterol. Some people use HMGCR to produce LDL in a different way, and that difference can interfere with the statin effect. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.